Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting.
暂无分享,去创建一个
Kelly Aubertin | Florence Gazeau | Claire Wilhelm | Nathalie Luciani | Didier Letourneur | C. Wilhelm | F. Gazeau | N. Luciani | D. Letourneur | S. Bonneau | K. Aubertin | C. Chauvierre | Stéphanie Bonneau | Cédric Chauvierre | A. Silva | Amanda K A Silva | Stephanie Bonneau
[1] Esther H Chang,et al. Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.
[2] T. Pellegrino,et al. Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials. , 2013, Nanoscale.
[3] Rebecca C Taylor,et al. Apoptosis: controlled demolition at the cellular level , 2008, Nature Reviews Molecular Cell Biology.
[4] Lianbo Yu,et al. Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.
[5] C Alexiou,et al. Clinical applications of magnetic drug targeting. , 2001, The Journal of surgical research.
[6] Victor C Yang,et al. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. , 2010, Biomaterials.
[7] M. Senge,et al. Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer †,‡ , 2011, Photochemistry and photobiology.
[8] Photophysical and photobiological properties of a sulfonated chlorin photosensitiser TPCS(2a) for photochemical internalisation (PCI). , 2013, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[9] I. Sargent,et al. Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.
[10] H. Mojzisova,et al. Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells , 2007, European Biophysics Journal.
[11] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[12] Dongmei Sun,et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] J. Rosenecker,et al. Insights into the mechanism of magnetofection using PEI‐based magnetofectins for gene transfer , 2004, The journal of gene medicine.
[14] Luigi Biancone,et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. , 2010, Kidney international.
[15] T. Park,et al. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[16] Florence Gazeau,et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. , 2006, Radiology.
[17] S. Lesieur,et al. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. , 2007, Radiology.
[18] Eleanor Stride,et al. Magnetic targeting and ultrasound mediated drug delivery: Benefits, limitations and combination , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[19] Shuming Nie,et al. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.
[20] Lutz Trahms,et al. Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[21] F. Kiessling,et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[22] Zhi-Feng Gan,et al. A novel magnetic fluid based on starch-coated magnetite nanoparticles functionalized with homing peptide , 2009 .
[23] H Anholt,et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. , 1999, Cancer research.
[24] K. Janes,et al. Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[25] M. Wood,et al. Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.
[26] M. Wood,et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.
[27] J. Freyssinet,et al. Membrane microparticles: two sides of the coin. , 2005, Physiology.
[28] Miqin Zhang,et al. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. , 2010, Advanced drug delivery reviews.
[29] C. Alexiou,et al. Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.
[30] K. Widder,et al. Magnetic guidance of drug‐carrying microspheres , 1978 .
[31] D. Pisetsky,et al. The role of microparticles in the pathogenesis of rheumatic diseases , 2010, Nature Reviews Rheumatology.
[32] L. Horstman,et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. , 2003, Thrombosis research.
[33] Gunther Hartmann,et al. SiRNA delivery with exosome nanoparticles , 2011, Nature Biotechnology.
[34] Vincent Dupuis,et al. Ultra magnetic liposomes for MR imaging, targeting, and hyperthermia. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[35] P. Singal,et al. Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.
[36] T. Galli,et al. Glutamate Controls tPA Recycling by Astrocytes, Which in Turn Influences Glutamatergic Signals , 2012, The Journal of Neuroscience.
[37] Véronique Préat,et al. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[38] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[39] J Henke,et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo , 2002, Gene Therapy.
[40] Christian Bergemann,et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. , 2008, Biomaterials.
[41] Crislyn D'Souza-Schorey,et al. Microvesicles: mediators of extracellular communication during cancer progression , 2010, Journal of Cell Science.
[42] J Ratajczak,et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication , 2006, Leukemia.
[43] S. Kadam,et al. Plasminogen activators: a comparison. , 2006, Vascular pharmacology.
[44] Wing-Cheung Law,et al. Phospholipid micelle-based magneto-plasmonic nanoformulation for magnetic field-directed, imaging-guided photo-induced cancer therapy. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[45] C. Santilli,et al. Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. , 2006, Colloids and surfaces. B, Biointerfaces.
[46] Alaa A. A. Aljabali,et al. CPMV-DOX delivers. , 2013, Molecular pharmaceutics.
[47] Patrick Couvreur,et al. Fe3O4/chitosan nanocomposite for magnetic drug targeting to cancer , 2012 .
[48] C. Wilhelm,et al. The role of cell-released microvesicles in the intercellular transfer of magnetic nanoparticles in the monocyte/macrophage system. , 2010, Biomaterials.
[49] P Reichardt,et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.
[50] M. Bureau,et al. Magnetic and photoresponsive theranosomes: translating cell-released vesicles into smart nanovectors for cancer therapy. , 2013, ACS nano.